Patent for Cannabinoid-based Therapy for Cachexia

India Globalization Capital, Inc. (IGC) announces that the company applied for a provisional patent based on a novel therapy that uses cannabinoid extracts from the cannabis plant for the treatment of cachexia. Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. In the U.S. it is estimated that a population of approximately 1.3 million are experiencing cachexia associated with cancer, multiple sclerosis, Parkinson's disease, HIV/AIDS and other progressive illnesses. Cancer induced anorexia cachexia is responsible for about 20% of all cancer deaths. "We believe our therapy, subject to controlled testing, could offer an alternative to a common and difficult condition that accompanies those suffering from severe illness. This patent filing for cachexia is an additional component of our core strategy that is intended to build a product portfolio of cannabinoid-based therapies for the treatment of a wide range of therapeutic indications including pain, epilepsy, and other niche severe terminal diagnosis, which are either life altering or life threatening. We believe we are developing a sustainable and differentiated segment in the cannabinoid-based bio-pharmaceutical sector and continue to further our specialty IP assets," said Ram Mukunda, IGC's CEO.